In this episode, Emily Heil, PharmD, MS, BCIDP, AAHIVP; Laila Woc-Colburn, MD; and Trevor Van Schooneveld, MD, FSHEA, FACP, discuss their approach to managing infections involving carbapenem-resistant Acinetobacter baumannii (CRAB), including: Mechanisms for β-lactam resistanceAdditional resistance mechanisms and virulence factors2023 IDSA guidance recommendations for moderate to severe CRAB infectionsThe latest clinical data by antimicrobial therapy/regimen:SulbactamMeropenem and colistinCarbapenem, sulbactam, and polymyxin BTetracyclinesCefiderocolSulbactam/durlobactam and carbapenems Program Director:Trevor Van Schooneveld, MD, FSHEA, FACP Professor, Division of Infectious DiseasesProgram Director, Infectious Diseases FellowshipMedical Director, Antimicrobial Stewardship ProgramUniversity of Nebraska Medical CenterOmaha, NebraskaFaculty:Emily Heil, PharmD, MS, BCIDP, AAHIVPAssociate ProfessorDepartment of PharmacyUniversity of Maryland School of PharmacyID Clinical Pharmacy SpecialistUniversity of Maryland Medical CenterBaltimore, MarylandLaila Woc-Colburn, MDAssociate ProfessorDivision of Infectious DiseasesEmory University School of Medicine Atlanta, GeorgiaContent based on a CME program supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Follow along with a downloadable slideset at: https://bit.ly/476v2wILink to full program: https://bit.ly/40Mmicz